Pancreatic cancer drug trial: Someone I know in their early 80s is considering taking part in a trial related to...

TL;DR: This trial tests whether daraxonrasib (a newer cancer drug) can prevent pancreatic cancer from coming back in people who've already been treated—it's a chance to try a promising new approach, but your loved one should understand the potential benefits, risks, and what being in a trial actually involves before deciding.

KEY POINTS:

• Daraxonrasib is an investigational drug that targets RAS mutations (found in about 85-90% of pancreatic cancers), and early data shows promise, but it's not yet proven to prevent recurrence
• Clinical trials for pancreatic cancer patients—especially those considering prevention after treatment—should be viewed as a serious treatment option from the start, not a last resort
• At age 80+, your loved one's overall health, ability to handle side effects, and quality-of-life priorities matter as much as the trial itself
• Dana-Farber is a high-quality academic center with expertise in pancreatic cancer, which is important for managing a complex trial
• The trial should include standard supportive care (managing side effects, nutrition, pain) alongside the experimental drug

NEXT STEP: Ask Dana-Farber for the trial's informed consent document and eligibility criteria in writing, then schedule a conversation with the trial team to discuss your loved one's specific health situation and concerns before committing.

---

[[FULL_ANSWER]]

Understanding Daraxonrasib and This Trial Opportunity

Your loved one is being offered a chance to participate in research on daraxonrasib (RMC-6236), an investigational drug designed to target RAS mutations in pancreatic cancer. According to recent research presented at the 2025 ASCO Gastrointestinal Cancer Symposium, daraxonrasib shows early promise in patients with previously treated pancreatic cancer.

What the Research Shows About Daraxonrasib

According to the latest clinical data, daraxonrasib is a pan-RAS inhibitor—meaning it can block a wider range of RAS mutations than older targeted drugs. Here's what we know:

The Promising Data:

• In a Phase I study of 127 patients with previously treated RAS-mutant pancreatic cancer, researchers saw "early and deep decreases in RAS mutant circulating tumor DNA" (the cancer DNA floating in the bloodstream)
• Median progression-free survival (time before cancer progresses) was 8.5 months for second-line treatment
• Median overall survival was 14.5 months
• The drug had a "manageable safety profile," meaning side effects were tolerable for most patients

Important Context:

• This is still investigational—the drug is NOT yet FDA-approved for pancreatic cancer
• A larger Phase III trial called RASolute 302 is currently ongoing to compare daraxonrasib against standard chemotherapy
• Your loved one's trial may be part of this larger research effort or a related study

Why This Matters for Pancreatic Cancer: According to pancreatic cancer experts cited in the guidelines, approximately 85-90% of pancreatic cancers carry a KRAS mutation (a type of RAS mutation). This makes RAS-targeted drugs potentially relevant for most pancreatic cancer patients. However, as one expert noted, "it has taken us literally decades to figure out how to target this mutation," so this represents genuinely new science.

---

Key Considerations for Someone in Their Early 80s

1. Age and Overall Health Matter—A Lot

Recent research from the GIANT study (presented at ASCO 2025) specifically examined chemotherapy in vulnerable older adults with metastatic pancreatic cancer. The findings are important for your loved one:

What the Research Found:

• Baseline quality-of-life factors strongly predicted how well patients tolerated treatment
• Key factors included: ability to perform daily activities, nutrition status, depression, and overall physical function
• White blood cell counts, depression, and BMI significantly correlated with severe side effects (Grade 3 toxicity)
• Among patients who received at least 4 weeks of therapy, median overall survival improved to 8.0 months (compared to 4.4-4.7 months for those who couldn't tolerate treatment)

What This Means: Your loved one's doctor should conduct a geriatric assessment—a formal evaluation of:

• Ability to perform daily activities (bathing, dressing, walking)
• Nutritional status and any swallowing difficulties
• Mental health (depression, anxiety, cognitive function)
• Current medications and how they might interact with daraxonrasib
• Social support (who can help with appointments, side effects)

This isn't just a formality—it predicts whether your loved one will actually benefit from the trial.

2. Understand What "Prevention" Means in This Context

The trial your loved one is considering is for people who have been "cleared by tests of current recurrence." This is important:

What This Means:

• Your loved one has completed initial treatment (surgery, chemotherapy, radiation, or combinations)
• Current imaging and blood tests show no evidence of cancer
• The trial is testing whether daraxonrasib can prevent cancer from returning

Important Reality Check: According to NCCN Guidelines for Pancreatic Cancer, after primary treatment, follow-up care includes:

• Regular imaging (CT or MRI scans)
• Blood tests (CA 19-9 tumor marker)
• Clinical monitoring for signs of recurrence

The trial is essentially asking: "Can we do better than just watching and waiting?" This is a legitimate scientific question, but it's different from treating active cancer.

3. Clinical Trials for Pancreatic Cancer Should Be Considered Early, Not as a Last Resort

According to Let's Win Pancreatic Cancer and NCCN Guidelines, there's been a shift in thinking about clinical trials:

The New Approach:

• For pancreatic cancer specifically, clinical trials should be considered as a possible treatment option from the very start
• This is because pancreatic cancer is so aggressive that patients may benefit from access to cutting-edge treatments immediately
• Trials are heavily regulated and monitored—patients in trials often receive MORE careful monitoring than those receiving standard care

For Your Loved One: Being in a trial doesn't mean abandoning standard care. According to the guidelines, pancreatic cancer trials typically include "standard of care plus" the experimental drug. This means:

• Your loved one will still receive all standard supportive care (managing side effects, nutrition, pain management)
• The trial adds the experimental drug on top of standard monitoring
• If the experimental drug isn't working, there are usually options to switch to other treatments

---

Critical Questions Your Loved One Should Ask Dana-Farber

About the Trial Itself:

1. "What is the primary goal of this trial?"

   • Is it testing whether daraxonrasib prevents recurrence? Improves survival? Improves quality of life?
   • How will success be measured?

2. "What phase is this trial in, and how many patients are enrolled?"

   • Phase I (safety) vs. Phase II (effectiveness) vs. Phase III (comparison to standard care) matters
   • Larger trials with more patients provide more reliable information

3. "Is this trial randomized, and if so, what are the treatment arms?"

   • Randomized means your loved one might be assigned to daraxonrasib OR a control group (observation or standard treatment)
   • Ask: "What's the chance my loved one gets the experimental drug vs. the control?"

4. "How long is the trial, and what does participation involve?"

   • How many visits to Dana-Farber?
   • How often will imaging and blood tests be done?
   • Can your loved one participate remotely or with a local oncologist, or must all care be at Dana-Farber?
   • What happens after the trial ends?

5. "What are the known side effects of daraxonrasib, and how are they managed?"

   • Ask for a written list of possible side effects
   • Ask specifically about side effects in older adults (the Phase I data may not have focused on this)
   • How will the trial team monitor for and manage side effects?

About Your Loved One's Specific Situation:

1. "Based on my health status, am I a good candidate for this trial?"

   • Ask the trial team to explain why they think your loved one would benefit
   • Ask about any concerns based on age, other medical conditions, or medications

2. "What happens if I develop side effects I can't tolerate?"

   • Can the drug dose be reduced?
   • Can your loved one withdraw from the trial?
   • What happens to follow-up care if they withdraw?

3. "What if my cancer recurs while I'm in the trial?"

   • Will your loved one have access to other treatments?
   • Does the trial allow for switching to standard chemotherapy if needed?

4. "What are my quality-of-life priorities, and how does this trial fit with them?"

   • This is a personal question, but important to discuss with the trial team
   • Recent research shows that quality-of-life factors (ability to do daily activities, maintain independence, spend time with family) are as important as survival statistics for older adults

About Logistics and Support:

1. "What are the costs, and what does insurance cover?"

   • The experimental drug is usually free (paid by the trial sponsor)
   • But travel, lodging, and additional testing may have costs
   • Ask if Dana-Farber has resources to help with travel or lodging

2. "What support services are available?"

   • Nutritionist, social worker, palliative care specialist?
   • Support groups for trial participants?
   • According to NCCN Guidelines, supportive care addressing pain, nutrition, and psychosocial needs is essential

3. "Can I get a second opinion from another pancreatic cancer specialist?"

   • This is always reasonable, especially for a major decision
   • Other major academic centers (Johns Hopkins, Memorial Sloan Kettering, UCSF) have pancreatic cancer expertise

---

What the Research Says About Older Adults in Cancer Trials

According to the GIANT study and NCCN Guidelines for Older Adult Oncology:

Factors That Predict Better Outcomes:

• Good nutritional status
• Ability to perform daily activities independently
• No depression or well-managed depression
• Strong social support
• Realistic expectations about what the trial can and cannot do

Red Flags That Suggest Caution:

• Difficulty with daily activities (bathing, dressing, walking)
• Poor nutrition or unintended weight loss
• Untreated depression or anxiety
• Isolation or lack of family/caregiver support
• Multiple other serious medical conditions

Your loved one's oncologist should discuss these factors honestly before enrolling.

---

The Bottom Line: What to Do Next

Before Your Loved One Commits:

1. Get the informed consent document in writing and read it carefully (or have someone read it with your loved one)

2. Request a detailed discussion with the trial team that includes:

   • The trial oncologist
   • A nurse coordinator
   • Ideally, a geriatric oncology specialist or palliative care specialist who can assess quality-of-life fit

3. Ask for time to think and discuss with family before deciding—don't feel pressured to decide immediately

4. Consider a second opinion from another pancreatic cancer specialist (this is standard practice and not insulting to Dana-Farber)

5. Discuss personal priorities with your loved one:

   • Is extending survival the top priority, or is maintaining quality of life and independence more important?
   • How much travel and medical appointments is your loved one willing to do?
   • What are realistic expectations?

According to NCCN Guidelines and Let's Win Pancreatic Cancer:

• Patients have the right to participate in clinical trials
• Patients also have the right to decline and pursue standard follow-up care
• Either choice is valid—what matters is that your loved one makes an informed decision aligned with their values

---

Sources Cited

This response is based on:

1. NCCN Guidelines for Patients: Pancreatic Cancer (2025) — specifically sections on clinical trials, supportive care, and treatment planning
2. Let's Win Pancreatic Cancer Research Highlights from ASCO GI 2025 — specifically the section on daraxonrasib (RMC-6236) showing Phase I data
3. GIANT Study (ECOG-ACRIN EA2186) — presented at ASCO 2025, examining chemotherapy in vulnerable older adults with pancreatic cancer
4. NCCN Guidelines for Older Adult Oncology — geriatric assessment and quality-of-life considerations
5. Let's Win Resources on Clinical Trials — emphasizing that trials should be considered early, not as a last resort, and that they include standard supportive care

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.